ABPI Plerixafor (Mozobil) - Case Studies

We use cookies to give you the best possible experience on our website.

Case Studies

The Innovation Case Studies section provides a comprehensive list of exemplar innovation projects from across the NHS. These innovations have been carefully selected to represent a range of ideas from medical technologies through to service and pathway re design. Each case study provides a background to the innovation and a contact for further information.

Click on the Case Study Browse area on the right to find examples by clinical area.

If you have an innovation case study you would like us to publish on the portal please contact the Innovation team at england.innovation@nhs.net

ABPI Plerixafor (Mozobil)

This is a novel therapy which stimulates mobilisation of stem cells from the bone marrow to the peripheral blood for collection.

This process is required in order to enable autologous stem cell transplantation, a treatment commonly utilised in lymphoma and multiple myeloma. A significant proportion of patients will fail to mobilise on conventional mobilisation regimens (G-CSF alone, or G-CSF in combination with chemotherapy such as cyclophosphamide), meaning that they cannot progress to transplant. Mobilisation with plerixafor is also more rapid which provides possible benefits to the NHS of decreased resource use and increased capacity.